BioCentury | Jan 9, 2012
Finance

A Remembrance: An authentic giant

...Partners in 1997.All told, Alex helped found more than 50 companies, including Geron Corp. and Connective Therapeutics Inc....
BioCentury | Nov 23, 2011
Top Story

Prospect Venture's Barkas passes away

...1991-97. He was the founding CEO of two biotechs while at KPCB: Geron Corp. and Connective Therapeutics Inc....
BioCentury | Oct 30, 2006
Finance

Connetics chronicles

...stock price is tracked against selected events since 1996. - Alexei Ku A. 02/01/96 - Connective Therapeutics...
BioCentury | Mar 31, 1997
Clinical News

Connetics regulatory update

...in rheumatoid arthritis. (CNCT name change, B6; Phase III trial enrolled, B10) Connetics Corp. (formerly Connective Therapeutics Inc....
BioCentury | Mar 31, 1997
Clinical News

Interferon gamma-1b: CNCT completed enrollment in its Phase III trial

...Connetics Corp. (formerly Connective Therapeutics Inc. , CNCT), Palo Alto, Calif. Product: Interferon gamma-1b Indication: Atopic dermatitis Status...
BioCentury | Mar 31, 1997
Company News

Connective Therapeutics autoimmune/inflammation, dermatology news

...trade on NASDAQ under the symbol CNCT. The company develops products for rheumatology and dermatology. Connective Therapeutics Inc....
BioCentury | Mar 3, 1997
Clinical News

Gamma interferon data

...over the trial. Side effects were minimal. Phase III results are expected by year end. Connective Therapeutics Inc....
BioCentury | Jan 27, 1997
Clinical News

Gamma interferon: CNCT began Phase II trials

Connective Therapeutics Inc. (CNCT), Palo Alto, Calif. Product: Gamma interferon Indication: Keloids Status: CNCT began Phase II trials in keloids, fibrotic growths that result from excessive collagen formation in the skin during healing. The placebo-controlled,...
BioCentury | Jan 13, 1997
Clinical News

ConXn recombinant relaxin data

...The Phase II trial should end by mid-year. (CNCT begins MS trial, see Clinical Status). Connective Therapeutics Inc....
BioCentury | Jan 13, 1997
Clinical News

Therapeutic vaccine targeted to T cell receptors: Phase I and II Update

Connective Therapeutics Inc. (CNCT), Palo Alto, Calif. Product: Therapeutic vaccine targeted to T cell receptors Indication: Multiple sclerosis Status: CNCT began Phase I/II testing of a T cell receptor vaccine designed to elicit a heightened...
Items per page:
1 - 10 of 35
BioCentury | Jan 9, 2012
Finance

A Remembrance: An authentic giant

...Partners in 1997.All told, Alex helped found more than 50 companies, including Geron Corp. and Connective Therapeutics Inc....
BioCentury | Nov 23, 2011
Top Story

Prospect Venture's Barkas passes away

...1991-97. He was the founding CEO of two biotechs while at KPCB: Geron Corp. and Connective Therapeutics Inc....
BioCentury | Oct 30, 2006
Finance

Connetics chronicles

...stock price is tracked against selected events since 1996. - Alexei Ku A. 02/01/96 - Connective Therapeutics...
BioCentury | Mar 31, 1997
Clinical News

Connetics regulatory update

...in rheumatoid arthritis. (CNCT name change, B6; Phase III trial enrolled, B10) Connetics Corp. (formerly Connective Therapeutics Inc....
BioCentury | Mar 31, 1997
Clinical News

Interferon gamma-1b: CNCT completed enrollment in its Phase III trial

...Connetics Corp. (formerly Connective Therapeutics Inc. , CNCT), Palo Alto, Calif. Product: Interferon gamma-1b Indication: Atopic dermatitis Status...
BioCentury | Mar 31, 1997
Company News

Connective Therapeutics autoimmune/inflammation, dermatology news

...trade on NASDAQ under the symbol CNCT. The company develops products for rheumatology and dermatology. Connective Therapeutics Inc....
BioCentury | Mar 3, 1997
Clinical News

Gamma interferon data

...over the trial. Side effects were minimal. Phase III results are expected by year end. Connective Therapeutics Inc....
BioCentury | Jan 27, 1997
Clinical News

Gamma interferon: CNCT began Phase II trials

Connective Therapeutics Inc. (CNCT), Palo Alto, Calif. Product: Gamma interferon Indication: Keloids Status: CNCT began Phase II trials in keloids, fibrotic growths that result from excessive collagen formation in the skin during healing. The placebo-controlled,...
BioCentury | Jan 13, 1997
Clinical News

ConXn recombinant relaxin data

...The Phase II trial should end by mid-year. (CNCT begins MS trial, see Clinical Status). Connective Therapeutics Inc....
BioCentury | Jan 13, 1997
Clinical News

Therapeutic vaccine targeted to T cell receptors: Phase I and II Update

Connective Therapeutics Inc. (CNCT), Palo Alto, Calif. Product: Therapeutic vaccine targeted to T cell receptors Indication: Multiple sclerosis Status: CNCT began Phase I/II testing of a T cell receptor vaccine designed to elicit a heightened...
Items per page:
1 - 10 of 35